TXMD stock: buy or sell?
June 26th, 2019
TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Should I buy TXMD stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, TherapeuticsMD stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is TherapeuticsMD stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we collected 6 ratings published for TXMD stock in the last 30 days. The general sentiment of these ratings is bullish for TXMD stock, with 5 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-11||JPMorgan Chase & Co.||n/a||Overweight|
|2019-5-7||Jefferies Financial Group||n/a||Hold|
TXMD stock analysis
Shares of TherapeuticsMD closed today at $2.49 and stepped up a nice 1.22%.
TherapeuticsMD stepped up a nice 1.22% and closed at $2.49. TXMD is soaring again after a 12.90% correction from its last top on June 19th at $2.79.
After boosting a super good 7.92% in a week last week, TherapeuticsMD closed this week at $2.49 and plummed a bloodcurdling -6.04%.
TXMD stock price history
TXMD stock went public on October 5th, 2017 with a price of $5.151. Since then, TXMD stock sliced a -51.70%, with a yearly average of -51.70%.
1: Adjusted price after possible price splits or reverse-splits.
TXMD stock historical price chart
TXMD stock reached 52-week highs at $7.18, and all-time highs 2018-06-08 with a price of 7.66.
TXMD stock price target is $10.00Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' TXMD stock price predictions in the hope that they will be met as they may be wrong and not met. We have 6 price targets for TherapeuticsMD stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-11||JPMorgan Chase & Co.||Lowers Target||$8.00||$6.00||-25%|
|2019-5-7||Jefferies Financial Group||Lowers Target||$5.00||$4.00||-20%|
|2019-2-11||Oppenheimer||Set Price Target||n/a||$14.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter publishing its last earnings report on February, TherapeuticsMD plummed a scary -51.08%. As soon as we get its actual EPS from the earnings report, we will update this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, TherapeuticsMD annual sales depreciated an awful -4.04% to $16.10 million USD from $16.78 marked in 2017. When comparing 2018 vs 2017, by contrast, profit margin (that is, the net income divided by revenues) plunged a -365.24% to -823.73%.
|2013||$8.78 M||-||$-28.42 M-323.7%||-|
|2014||$15 M||71.14%||$-54.22 M-360.8%||90.77%|
|2015||$20 M||34.05%||$-85.08 M-422.4%||56.92%|
|2016||$19 M||-3.90%||$-89.88 M-464.3%||5.64%|
|2017||$17 M||-13.32%||$-76.93 M-458.5%||-14.41%|
|2018||$16 M||-4.04%||$-132.62 M-823.7%||72.40%|
Quarterly financial resultsTherapeuticsMD posted $5.09 M in revenues for 2018-Q4, a 46.52% improvement compared to previous quarter. Reported quarter income marked $-39.39 million with a profit margin of -773.96%. Profit margin boosted a 251.08% compared to previous quarter when profit margin was -1,025.04%. When comparing sales to same quarter last year, TherapeuticsMD sales marked a super good increase and climbed a 23.41%.
|2017-Q1||$4 M||-||$-21.16 M-530.3%||-|
|2017-Q2||$4 M||6.52%||$-19.68 M-463.1%||-6.99%|
|2017-Q3||$4 M||3.94%||$-14.66 M-332.0%||-25.48%|
|2017-Q4||$4 M||-6.64%||$-21.43 M-519.5%||46.12%|
|2018-Q1||$4 M||-8.51%||$-24.40 M-646.7%||13.88%|
|2018-Q2||$4 M||-0.28%||$-33.22 M-882.8%||36.13%|
|2018-Q3||$3 M||-7.69%||$-35.61 M-1025.0%||7.18%|
|2018-Q4||$5 M||46.52%||$-39.39 M-774.0%||10.63%|
TherapeuticsMD ownershipWhen you are planning to invest in shares of a stock, it's worth to check its ownership structure.
TherapeuticsMD shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 17.76% of all shares.
In case of TherapeuticsMD stock, 78.61% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for TXMD stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to TherapeuticsMD:
|Market cap||$600.6 M||$97.2 B||$63.0 M||$311.7 M||$215.3 M|
|Total shares||241.2 M||1,480.0 M||43.7 M||33.8 M||37.9 M|
|Float shares||198.7 M||1,480.0 M||25.5 M||21.9 M||24.3 M|
|- Institutional holdings (%)||78.6%||71.9%||54.2%||121.2%||86.6%|
|- Insider holdings (%)||17.8%||0.1%||1.3%||2.1%||28.2%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$2.38 - $2.52|
|Average true range||$0.27|
|50d mov avg||$3.37|
|100d mov avg||$4.36|
|200d mov avg||$4.74|
TherapeuticsMD performanceTo better understand TherapeuticsMD performance you must compare its gains with other related stocks in same sector or industry. We compared TherapeuticsMD against AbbVie, Agile Therapeutics, AMAG Pharmaceuticals, Lannett and Pfizer in the following table: